Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arena Pharmaceutical (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,372,137
  • Shares Outstanding, K 39,260
  • Annual Sales, $ 123,980 K
  • Annual Income, $ -22,520 K
  • 36-Month Beta 1.50
  • Price/Sales 10.54
  • Price/Cash Flow N/A
  • Price/Book 6.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.53 +14.90%
on 12/20/17
41.92 -19.06%
on 01/05/18
+3.70 (+12.24%)
since 12/15/17
3-Month
24.33 +39.46%
on 11/08/17
41.92 -19.06%
on 01/05/18
+8.37 (+32.75%)
since 10/16/17
52-Week
11.30 +200.27%
on 05/18/17
41.92 -19.06%
on 01/05/18
+19.73 (+138.94%)
since 01/13/17

Most Recent Stories

More News
Orexigen Struggles as Contrave Commercialization Costs Rise

Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

OREX : 1.20 (-0.83%)
NVO : 55.31 (+0.49%)
VVUS : 0.48 (-5.88%)
ARNA : 33.91 (-2.98%)
Kaplan Fox & Kilsheimer LLP Announces Proposed Settlement in the Arena Securities Litigation

The following statement is being issued by Kaplan Fox & Kilsheimer LLP regarding the Arena Securities Litigation.

ARNA : 33.91 (-2.98%)
Arena Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 36th Annual J.P. Morgan Healthcare...

JPM : 112.23 (-0.39%)
ARNA : 33.91 (-2.98%)
Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, and Everest Medicines Limited ("Everest"), a...

ARNA : 33.91 (-2.98%)
Market Trends Toward New Normal in Arena Pharmaceuticals, National Fuel Gas, Capitol Federal Financial, Comfort Systems, National Instruments, and Navistar International -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena Pharmaceuticals, Inc....

NAV : 44.10 (-2.86%)
CFFN : 13.52 (-1.60%)
FIX : 43.10 (-2.27%)
ARNA : 33.91 (-2.98%)
NATI : 44.69 (+0.86%)
NFG : 55.71 (-0.77%)
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study

Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.

LGND : 146.30 (-1.75%)
ARNA : 33.91 (-2.98%)
ABBV : 102.47 (+2.12%)
PFE : 36.60 (+0.16%)
Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative colitis (UC). Etrasimod is an investigational-stage, oral,...

ARNA : 33.91 (-2.98%)
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat

Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.

LGND : 146.30 (-1.75%)
EBS : 48.81 (+2.67%)
ARNA : 33.91 (-2.98%)
EXEL : 29.63 (-2.47%)
Biotech Stocks on Investors' Radar -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and AveXis

If you want a Stock Review on ARLZ, ARNA, ARWR, or AVXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Tuesday, November 07, 2017, US markets saw...

ARLZ : 1.70 (-4.49%)
ARWR : 5.59 (-2.27%)
ARNA : 33.91 (-2.98%)
AVXS : 105.00 (-10.64%)
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today provided a corporate update and reported financial results for the third quarter ended September 30, 2017.

ARNA : 33.91 (-2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Key Turning Points

2nd Resistance Point 36.86
1st Resistance Point 35.91
Last Price 33.91
1st Support Level 34.41
2nd Support Level 33.86

See More

52-Week High 41.92
Last Price 33.91
Fibonacci 61.8% 30.22
Fibonacci 50% 26.61
Fibonacci 38.2% 23.00
52-Week Low 11.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.